Pfizer (PFE) stops developing hep-C drug on strategic review - DJN
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Join SI Premium – FREE
Pfizer, Inc. (NYSE: PFE) stops developing hep-C drug on strategic review, according to Dow Jones headlines.
Shares are down 0.4 percent Friday.
Shares are down 0.4 percent Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA clears Implantica's RefluxStop implant for U.S. market
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
Create E-mail Alert Related Categories
FDA, General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
